Overview

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Status:
RECRUITING

Trial end date:
2029-10-26

Target enrollment:

Participant gender:

Summary

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase:

PHASE3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

dostarlimab